Risvodetinib demonstrated to be safe and well-tolerated with preliminary clinical benefits Risvodetinib demonstrated to be the first treatment to reduce alpha-synuclein pathology, widely recognized as ...
ATLANTA and BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine ...
ATLANTA and BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that are associated with activation of Abelson ...
ATLANTA and BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine ...
President John Mahama will lead the executive arm of government to attend a high profile three day international conference on leadership in Africa. Dubbed the African Biblical Leadership Initiative ...
Study aims to evaluate promising therapeutics that could slow or halt progression of Parkinson’s disease in prodromal patients ATLANTA and BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- ABLi Therapeutics ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results